Drug General Information
Drug ID
D04AGG
Drug Name
Favipiravir
Synonyms
AIDS121660; Favipiravir (JAN/INN); 3-bromo-5-hydroxy-4-methyl-2,6-dinitro-benzoic Acid; T705
Drug Type
Small molecular drug
Indication Coronavirus Disease 2019 (COVID-19) Phase 3 [1], [2]
Other Indication Influenza virus infection Approved [3]
Therapeutic Class
Antiviral Agents
Company
Toyama Chemical
Structure
Download
2D MOL

3D MOL

Formula
C8H5BrN2O7
Canonical SMILES
CC1=C(C(=C(C(=C1Br)[N+](=O)[O-])C(=O)O)[N+](=O)[O-])O
InChI
1S/C8H5BrN2O7/c1-2-4(9)5(10(15)16)3(8(13)14)6(7(2)12)11(17)18/h12H,1H3,(H,13,14)
InChIKey
GIZRPXSAIKOADF-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target
Target(s) COVID-19 RNA-directed RNA polymerase (RdRp) Target Info Inhibitor [4], [5]
Favipiravir effectively inhibits the RNA-dependent RNA polymerase of RNA viruses and a recent study reported its activity against 2019-nCoV (EC50 = 61.88 microM in Vero E6 cells).
References
1 ClinicalTrials.gov (NCT04336904) Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
2 ChiCTR.org.cn (ChiCTR2000030254) the Efficacy and Safety of Favipiravir for novel coronavirusinfected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. Posted April 15, 2020.
5 Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.